Loading...
•
Dec 31, 2021
CRISPR Therapeutics Q4 2021 Earnings Report
CRISPR Therapeutics reported financial results for Q4 2021, highlighting progress in clinical programs and collaborations.
Key Takeaways
CRISPR Therapeutics reported a net loss of $141.2 million for the fourth quarter of 2021, compared to a net loss of $107.0 million for the fourth quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $2,379.1 million as of December 31, 2021. Total collaboration revenue was $12.3 million for the fourth quarter of 2021 compared to $0.2 million for the fourth quarter of 2020.
More than 70 patients have been dosed with CTX001 across CLIMB-Thal-111 and CLIMB-SCD-121, with enrollment complete and regulatory submissions planned for late 2022.
Initiated and began dosing patients in the pivotal trial of CTX110, targeting CD19+ B-cell malignancies, with additional data expected in 2022.
Top-line data expected in 1H2022 for ongoing CTX120 and CTX130 clinical trials.
First patient dosed in Phase 1 clinical trial of VCTX210 for the treatment of type 1 diabetes (T1D).
Revenue by Segment
Forward Guidance
CRISPR Therapeutics anticipates continued progress across its portfolio in 2022, expecting a productive year as it enters a new phase of growth.
Positive Outlook
- Planned regulatory submissions for CTX001 in late 2022.
- Additional data expected to be reported in 2022 for CTX110 pivotal trial.
- Top-line data expected in the first half of 2022 for CTX120 and CTX130 clinical trials.
- Advancement of in vivo programs with multiple programs expected to move into the clinic in the next 18 to 24 months.
- Strong capital position to advance pipeline and platform.
Challenges Ahead
- Uncertainties inherent in the initiation and completion of preclinical studies.
- Uncertainties about regulatory approvals to conduct trials or to market products.
- Potential impacts due to the coronavirus pandemic.
- Uncertainties regarding the intellectual property protection.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...